CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 26,877 enrolled
Drug / intervention
Genome Informed Risk Assessment (GIRA) reportother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05277116
NCT05277116N/AActive

The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment

Vanderbilt University Medical Center·interventional·Posted Mar 14, 2022·Updated Aug 29, 2025

In Brief

A clinical study evaluating Genome Informed Risk Assessment (GIRA) report for Genetic Disease. Active but no longer recruiting, targeting 26,877 participants across 12 sites.

Detailed Summary

The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a prospective study, with diverse and underserved participants, across ten eMERGE study sites to evaluate clinical implementation of a Genome Informed Risk Assessment (GIRA) tool that combines genetic, family history, and clinical risk information from participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenetic Disease
CountriesUnited States
Collaborators--

Timeline

N/AActive
202220232024202520262027
First PostedMar 14, 2022
Enrollment StartFeb 16, 2022
Primary CompletionApr 30, 2026
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 4.3 years ago

Interventions

Genome Informed Risk Assessment (GIRA) reportother

A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.